Table 2. Subgroup analyses for assessing prognosis of endometriosis-associated ovarian cancer.
| |
|
|
|
Heterogeneity |
|
|
|---|---|---|---|---|---|---|
| Category | No. of studies with references | HR | 95% CI | P | I2 | Model used |
|
Progression-free survival | ||||||
| Histology | ||||||
| Clear cell carcinoma |
3 |
0.835 |
0.531–1.312 |
0.150 |
47.280 |
Fixed effect |
| Adjustment for potential confounding factors | ||||||
| Age | 3 | 1.263 | 0.832–1.916 | 0.415 | 0 | Fixed effect |
| Age, optimal debulking surgery |
2 |
1.155 |
0.725–1.842 |
0.303 |
5.928 |
Fixed effect |
|
Overall survival | ||||||
| Assessment of endometriosis | ||||||
| Histology |
6 |
0.730 |
0.553–0.964 |
0.251 |
24.352 |
Fixed effect |
| FIGO stage | ||||||
| Early stage (I–II) | 3 | 0.753 | 0.494–1.147 | 0.979 | 0 | Fixed effect |
| Advanced stage (III–IV) |
3 |
0.908 |
0.590–1.397 |
0.977 |
0 |
Fixed effect |
| Histology | ||||||
| Clear cell carcinoma |
3 |
0.820 |
0.352–1.911 |
0.098 |
56.856 |
Random effects |
| Adjustment for potential confounding factors | ||||||
| Age | 6 | 0.771 | 0.647–0.918 | 0.272 | 21.432 | Fixed effect |
| Age, grade | 4 | 0.840 | 0.578–1.221 | 0.267 | 24.086 | Fixed effect |
| Age, grade, platinum-based chemotherapy | 3 | 0.966 | 0.626–1.491 | 0.303 | 16.295 | Fixed effect |
Abbreviations: CI=confidence interval; FIGO=International Federation of Gynecology and Obstetrics; HR=hazard ratio.